Ernexa Therapeutics

CompanyUnited States

Ernexa Therapeutics develops one asset, preclinical (ERNA-101 in cancer). Mostly other; based in the United States.

1
Asset
Furthest stage
Preclinical
0
Trials
0
Signals

Pipeline

1
  • ERNA-101

    Oncology therapeutic designed to clear tumors in combination with anti-PD-1.

    Preclinical, Other, cancer, solid tumor

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Similar companies6

Intelligence